成纖維細胞生長因子 19 (FGF-19) 是 FGFs 亞家族的成員，包括 FGF-21 和 FGF-23，每個成員都作為營養代謝的重要規律。 內分泌 FGF-19 的主要來源是迴腸，餐後膽汁酸釋放到腸道以誘導 FGF-19 的表達。循環 FGF-19 在維持適當的膽汁酸穩態方面起著重要作用。在高血糖、肥胖動物模型中的幾項藥理學研究表明，FGF-19 可以提高代謝率並降低血清葡萄糖和肝臟甘油三酯和膽固醇水平。與胰島素一樣，FGF-19 作為餐後激素發揮作用，控制肝臟蛋白質合成、糖原合成和糖異生，但不刺激脂肪生成。

該測定是定量夾心ELISA。免疫板預先塗有對人 FGF-19 具有特異性的兔多克隆抗體。標準品和样品被移入孔中，任何存在的人 FGF-19 都被固定的抗體結合。洗去任何未結合的物質後，將生物素標記的特異於人 FGF-19 的多克隆抗體添加到孔中。在去除任何未結合試劑的洗滌步驟後，加入鏈黴親和素-HRP 偶聯物 (STP-HRP)。在最後一個洗滌步驟後，加入 HRP 底物溶液，顏色與最初結合的人 FGF-19 的量成比例。 停止測定並使用酶標儀測定孔的光密度。由於吸光度的增加與捕獲的人 FGF-19 的量成正比，因此可以從每個分析中包含的參考曲線中插入未知樣品濃度。

一種。 標準曲線的典型代表

以下標準曲線僅供演示。應為每組樣品測定生成標準曲線。 

B. 敏感性

該測定法可測量的 FGF-19 的最低水平為 31.2 皮克/毫升。

C. 特異性

該檢測中使用的抗體對人 FGF-19 具有特異性，不會與人脂聯素、FGF-21、FABP4、LCN2、RBP4 和 PAI-1 發生交叉反應。

D. 精度

測定內精密度（測定內的精密度）CV <4.5%。

測定間精密度（測定之間的精密度）CV <5.6%。

1. Fang Q, Li H, Song Q, Yang W, Hou X, Ma X, Lu J, Xu A, Jia W. Serum fibroblast growth factor 19 levels are decreased in Chinese subjects with impaired fasting glucose and inversely associated with fasting plasma glucose levels. Diabetes Care. 2013 Sep 1;36(9):2810-4.
2. Chen DL, Liess C, Poljak A, Xu A, Zhang J, Thoma C, Trenell M, Milner B, Jenkins AB, Chisholm DJ, Samocha-Bonet D. Phenotypic characterization of insulin-resistant and insulin-sensitive obesity. The Journal of Clinical Endocrinology & Metabolism. 2015 Nov 1;100(11):4082-91.
3. Chen DL, Brown R, Liess C, Poljak A, Xu A, Zhang J, Trenell M, Jenkins A, Chisholm D, Samocha-Bonet D, Macefield VG. Muscle sympathetic nerve activity is associated with liver insulin sensitivity in obese non-diabetic men. Frontiers in physiology. 2017 Feb 28;8:101.
4. Zhang J, Li H, Zhou H, Fang L, Xu J, Yan H, Chen S, Song Q, Zhang Y, Xu A, Fang Q. Lowered fasting chenodeoxycholic acid correlated with the decrease of fibroblast growth factor 19 in Chinese subjects with impaired fasting glucose. Scientific reports. 2017 Jul 20;7(1):1-1.
5. Hu X, Xiong Q, Xu Y, Zhang X, Pan X, Ma X, Bao Y, Jia W. Association of serum fibroblast growth factor 19 levels with visceral fat accumulation is independent of glucose tolerance status. Nutrition, Metabolism and Cardiovascular Diseases. 2018 Feb 1;28(2):119-25.
6. Wong YK, Cheung CY, Tang CS, Au KW, Hai JS, Lee CH, Lau KK, Cheung BM, Sham PC, Xu A, Lam KS. Age-biomarkers-clinical risk factors for prediction of cardiovascular events in patients with coronary artery disease. Arteriosclerosis, thrombosis, and vascular biology. 2018 Oct;38(10):2519-27.
7. Tang A, Coster AC, Tonks KT, Heilbronn LK, Pocock N, Purtell L, Govendir M, Blythe J, Zhang J, Xu A, Chisholm DJ. Longitudinal changes in insulin resistance in normal weight, overweight and obese individuals. Journal of clinical medicine. 2019 May;8(5):623.
8. Zhang J, Li H, Bai N, Xu Y, Song Q, Zhang L, Wu G, Chen S, Hou X, Wang C, Wei L. Decrease of FGF19 contributes to the increase of fasting glucose in human in an insulin-independent manner. Journal of endocrinological investigation. 2019 Sep;42(9):1019-27.
9. Harari A, Coster AC, Jenkins A, Xu A, Greenfield JR, Harats D, Shaish A, Samocha-Bonet D. Obesity and insulin resistance are inversely associated with serum and adipose tissue carotenoid concentrations in adults. The Journal of nutrition. 2020 Jan 1;150(1):38-46.
10. Hu J, Liu Z, Tong Y, Mei Z, Xu A, Zhou P, Chen X, Tang W, Zhou Z, Xiao Y. Fibroblast Growth Factor 19 Levels predict subclinical atherosclerosis in men with type 2 diabetes. Frontiers in Endocrinology. 2020 May 22;11:282.
11. Zhang J, Ni Y, Qian L, Fang Q, Zheng T, Zhang M, Gao Q, Zhang Y, Ni J, Hou X, Bao Y. Decreased Abundance of Akkermansia muciniphila Leads to the Impairment of Insulin Secretion and Glucose Homeostasis in Lean Type 2 Diabetes. Advanced Science. 2021 Jun 4:2100536.
12. Hu JY, Zou HL, Li YH, Nie DY, Chao C, Liu JH, Ding J, Zhou ZG, Xiao Y. Serum fibroblast growth factor 19 (FGF19) levels are associated with atherogenic dyslipidemia in patients with type 2 diabetes. Chinese medical journal. 2021 Sep 20;134(18):2243.
13. Cheng F, Ng NY, Tam CH, Zhang Y, Lim CK, Jiang G, Ng AC, Yau TT, Cheung LP, Xu A, Chan JC. Association between FGF19, FGF21 and lipocalin-2, and diabetes progression in PCOS. Endocrine connections. 2021 Oct 1;10(10):1243-52.